Medical Condition News

RSS

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

An analysis demonstrating the ability of DX-88 (ecallantide) to resolve symptoms of acute hereditary angioedema (HAE) attacks in all anatomic locations and to sustain effect will be presented in an oral presentation this week at the American College of Allergy, Asthma and Immunology (ACAAI) 2009 Annual Meeting in Miami Beach.

9 Nov 2009

C1-INH concentrate, an effective therapy to treat acute swelling attacks for HAE

Patients reported C1-esterase inhibitor (C1-INH) concentrate is an effective therapy in treating acute swelling attacks at any body location for HAE, a rare and serious genetic disorder, according to data presented today at the 2009 American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting.

9 Nov 2009

LLS to participate in Gap's Give & Get program to support its blood cancer research

The Leukemia & Lymphoma Society (LLS) will again be participating in Gap Inc.'s Give & Get program, which in its first two campaigns this past spring and summer, garnered more than $1 million to support LLS's blood cancer research funding and patient education and support services.

7 Nov 2009

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Registration is now open for the Society of Interventional Radiology's "Image-guided Interventional Oncology (IO) Therapies" Webinar, which will provide the latest updates on percutaneous and transcatheter treatment of liver tumors, kidney tumor ablation and lung tumor ablation.

7 Nov 2009

Study finds brain changes and severe depression in political detainees experiencing head injury

Depression and other emotional symptoms in survivors of torture and other traumatic experiences may be exacerbated by the effects of head injuries, according to a study from the Harvard Program in Refugee Trauma (HPRT), based in the Massachusetts General Hospital (MGH) Department of Psychiatry.

7 Nov 2009

Congressman Fattah lends full support to The Pancreatic Cancer Research and Education Act

"Pancreatic cancer is a rare and perplexing disease, yet it is the fourth leading cause of death by cancer in the United States. This year, more than 42,000 Americans will be diagnosed with the disease and more than 35,000 will die from it. That number is far too high.

7 Nov 2009

PET scanning emerges as an important tool in the evaluation of lung cancer

A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting.

7 Nov 2009

Seminar highlights the importance of chronic health issues

With 125 million Americans challenged by at least one chronic illness and 22% of that number facing life with two or more chronic illnesses, early, smart estate and financial planning can make the difference between maximizing control over your life or falling victim to its exigencies.

7 Nov 2009

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus.

7 Nov 2009

Researchers find compound that reverses type 1 myotonic dystrophy

A compound already used to treat pneumonia could become a new therapy for an inherited muscular wasting disease, according to researchers at the University of Oregon and the University of Rochester School of Medicine and Dentistry in New York.

7 Nov 2009

Halozyme Therapeutics announces results of its insulin variability study

Halozyme Therapeutics, Inc. today announced insulin variability study results that demonstrated reduced intrasubject absorption variability for the combination of lispro, a meal time analog insulin, plus PH20 (hyaluronidase) compared to subcutaneous injection of lispro alone.

7 Nov 2009

Rituximab drug potentially effective for treating Graves' eye disease, shows study

A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease.

7 Nov 2009

Only 30 per cent of bystanders in Toronto who witness a cardiac arrest willing to help, say researchers

Researchers at St. Michael's Hospital working in conjunction with EMS services, paramedics and fire services across Ontario found that a bystander who attempts cardiopulmonary resuscitation (CPR) can quadruple the survival rate to over 50 per cent. But Dr. Laurie Morrison and the research team at Rescu (www.rescu.ca) have found only 30 per cent of bystanders in Toronto are willing to help, one of the lowest rates of bystanders helping others in the developed world.

7 Nov 2009

Increased use of CAS procedures to treat carotid stenosis associated with adverse clinical outcomes

Among eligible Medicare beneficiaries, increased use of carotid arterial stenting (CAS) procedures to treat carotid stenosis-the narrowing of the carotid artery-is associated with higher rates of mortality and adverse clinical outcomes, including heart attack and stroke, according to researchers from the University of Pennsylvania School of Medicine.

7 Nov 2009

Health experts report rising number of oral cancer in younger age groups

Mouth cancer (also called oral cancer) is a malignant growth which can occur in any part of the mouth including the lips and tongue. In the UK, the numbers of new cases have risen by over 41 per cent over the last ten years(1).

7 Nov 2009

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

7 Nov 2009

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

Genetix Pharmaceuticals, a leader in gene therapy of somatic stem cells, announced today the company’s clinical program to treat Adrenoleukodystrophy (ALD). The company is developing a gene therapy product in collaboration with Professor Patrick Aubourg and Doctor Nathalie Cartier of the National Institute of Health and Medical Research (INSERM).

7 Nov 2009

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.

7 Nov 2009

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today the latest recipient of the End Duchenne Grant Award Program.

6 Nov 2009

Gonorrhea medication may help fight cancer

Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. The newest surprise discovered by researchers at the Johns Hopkins University School of Medicine is a gonorrhea medication that might help battle cancer.

6 Nov 2009

Medical Condition News

Evaluation of DX-88 to resolve symptoms of acute HAE attacks to be presented

C1-INH concentrate, an effective therapy to treat acute swelling attacks for HAE

LLS to participate in Gap's Give & Get program to support its blood cancer research

Webinar: Latest updates on percutaneous and transcatheter treatment of liver, kidney and lung tumor ablation

Study finds brain changes and severe depression in political detainees experiencing head injury

Congressman Fattah lends full support to The Pancreatic Cancer Research and Education Act

PET scanning emerges as an important tool in the evaluation of lung cancer

Seminar highlights the importance of chronic health issues

Report provides critical strategic insight for companies with a stake in the market for rheumatology therapies

Researchers find compound that reverses type 1 myotonic dystrophy

Halozyme Therapeutics announces results of its insulin variability study

Rituximab drug potentially effective for treating Graves' eye disease, shows study

Only 30 per cent of bystanders in Toronto who witness a cardiac arrest willing to help, say researchers

Increased use of CAS procedures to treat carotid stenosis associated with adverse clinical outcomes

Health experts report rising number of oral cancer in younger age groups

Graceway Pharmaceuticals acquires global rights to Gilead Sciences' GS 9191 anti-proliferative agent

Genetix Pharmaceuticals develops a gene therapy product to treat ALD

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

Gonorrhea medication may help fight cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News